Mary Susan Pruzinsky, MD Otolaryngology - Otolaryngology/Facial Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2710 Saint Francis Dr, Ste 411, Waterloo, IA 50702 Phone: 319-272-5000 Fax: 319-272-5825 |
Kenny David Rodriguez, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2515 Cyclone Dr Ste B, Waterloo, IA 50701 Phone: 319-888-8044 |
Ann F Bell, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 2710 St Francis Dr Ste 411, Waterloo, IA 50702 Phone: 319-272-5000 Fax: 319-272-5825 |
Dr. Dov Rotenberg, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 2710 Saint Francis Dr, Suite 411, Waterloo, IA 50702 Phone: 319-272-5000 Fax: 319-272-5825 |
David James Congdon, MD Otolaryngology - Otolaryngology/Facial Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2515 Cyclone Dr Ste B, Waterloo, IA 50701 Phone: 319-888-8044 |
Dr. William Richards Burgman, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 2710 Saint Francis Dr, Suite 411, Waterloo, IA 50702 Phone: 319-272-5805 |
News Archive
Researchers at UCLA have developed a mathematical model that mimics a particularly nasty and ongoing outbreak in the Los Angeles County Jail (LACJ) of the flesh eating bacteria Staphylococcus Aureus.
For the first time, researchers have confirmed an association between a common magnetic resonance imaging (MRI) contrast agent and abnormalities on brain MRI, according to a new study published online in the journal Radiology. The new study raises the possibility that a toxic component of the contrast agent may remain in the body long after administration.
Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific Aegis5-14 Film, the company's new advanced single-use film that is ideal for the most demanding cell culture and bioprocessing applications in drug development and biomanufacturing.
UK Bioscientists are transferring GM knowledge and technology from the developed to the developing world to help fight future food insecurity in Sub-Saharan Africa.
Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced it has entered into an agreement with Piscataway, N.J.-based University of Medicine and Dentistry of New Jersey (UMDNJ) to conducted a Phase 1 clinical trial with its proprietary, patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD).
› Verified 8 days ago